Myasthenia Gravis

Myasthenia Gravis Foundation of Latvia

In our country the incidence of this disease is average four cases per hundred thousand population (world- four, five even up to 50 cases by different authors). Latvia currently has about 250 Myastheni gravis patients, about 15 are children and adolescents up to 14 years. Although the disease is generally progressive process, it is one of the pathological conditions that can result in effective medical treatment and the patient's condition improving-70% of cases can be good or very good results.

Conclusion.
It is a paradox that Myasthenia treatment is still so unspecific. Myasthenia Gravis is the best characterised autoimmune disease with well-defined pathogenetic antibodies that impair function through the destruction and inhibition of muscle cell AChR. Still our therapeutic immunosuppression is aimed at general mechanisms of the immune system. The external causes for Myasthenia are actuallly unknown. The ultimate aim of eradicating Myasthenia by removing the cause of the disease seems still far away.
There is a need for better and more focused treatment, not by random and individual off-label use of the drugs.
…